Cambridge, UK 1/28/19—Life science reagent company Abcam has purchased Calico Biolabs for an undisclosed amount. Calico Biolabs provides recombinant rabbit monoclonal antibodies, including CAL antibodies for immune-oncology targets, as well as custom antibodies for companion diagnostics through partnerships with diagnostics and pharmaceutical companies. “This acquisition strategically expands our leadership in recombinant rabbit monoclonal antibody technology,” stated Joyce Young, vice president of Custom Services at Abcam. “The combination of our complementary antibody engineering capabilities will further support our mission to provide our customers with access to the best antibodies for both today’s and tomorrow’s targets of interest.”

According to an Abcam spokesperson, the acquisition will strengthen the company’s presence in the diagnostics/companion diagnostics sector. “In addition, it will enhance our custom service capabilities and reinforce our leadership position in rabbit monoclonal antibody technology,” she said. “This will enable us to further enhance access to high-quality antibodies for key areas of research and diagnostic development, including immuno-oncology.” Calico Biolabs has eight employees, who are primarily focused on custom antibody engineering, according to Abcam.